Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
1099 On Other Exchanges
1099 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

sinopharm group co-h (1099) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SINOPHARM GROUP CO-H (1099)

Related News

No related news articles were found.

sinopharm group co-h (1099) Related Businessweek News

View More BusinessWeek News

sinopharm group co-h (1099) Details

Sinopharm Group Co.,Ltd., together with its subsidiaries, distributes pharmaceutical and healthcare products in the People’s Republic of China. The company operates in three segments: Pharmaceutical Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. This segment distributes medicines, medicine devices, and pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. The Retail Pharmacy segment operates or franchises a network of retail drug stores. As of December 31, 2014, this segment had 2,096 retail pharmacies, which included 1,747 retail pharmacies operated by company and 349 operated by franchisees. The Other Business segment produces and sells pharmaceutical products, chemical reagents, and laboratory supplies. The company also distributes building decoration, communication, and clothing products, as well as chemical reagents; imports and exports goods and technology; and provides business consulting, import agency services, other miscellaneous services, etc. In addition, it is involved in the real estate development, property rental, planting, and property management activities; provision of health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services; and distribution of commodities and construction materials. Further, the company engages in enterprise management, consulting, technology services, and research and development in the field of biotechnology professional; cargo agency, warehousing, and shipping services; manufacture and trade of Chinese herbal medicines. The company was founded in 2003 and is based in Shanghai, China. Sinopharm Group Co.,Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.

52,912 Employees
Last Reported Date: 09/7/15
Founded in 2003

sinopharm group co-h (1099) Top Compensated Officers

President, Executive Director and Member of S...
Total Annual Compensation: CNY2.8M
Head of Auditing Department and Supervisor
Total Annual Compensation: CNY895.0K
Compensation as of Fiscal Year 2014.

sinopharm group co-h (1099) Key Developments

Sinopharm Group Co.,Ltd. Announces Consolidated Unaudited Earnings Results for the Six Months Ended June 30, 2015

Sinopharm Group Co.,Ltd. announced consolidated unaudited earnings results for the six months ended June 30, 2015. For the period, the company reported revenues of RMB 111,057,454,000 compared with RMB 94,835,673,000 for the same period a year ago. Operating profit was RMB 4,621,841,000 compared with RMB 3,921,869,000 for the same period a year ago. Profit before income tax was RMB 3,753,504,000 compared with RMB 3,004,166,000 for the same period a year ago. Profit for the period attributable to shareholders of the company was RMB 1,913,845,000 or RMB 0.69 per basic and fully diluted share compared with RMB 1,465,462,000 or RMB 0.57 per basic and fully diluted share for the same period a year ago. The increase in Revenue was due to the increase in revenue from the Group's pharmaceutical distribution business as well as retail pharmacy business. The Group's revenue and market share grew much faster than the overall development of the pharmaceutical market in China, and outperformed industry average. The Group's cash inflow from operations primarily derives from collections from the sale of products and services in its pharmaceutical distribution, retail pharmacy and other business segments. During the Reporting Period, the Group's net cash generated from operating activities amounted to RMB 1,837.09 million, representing a decrease of RMB 28.31 million from RMB 1,865.40 million for the six months ended 30 June 2014. The Group's capital expenditures primarily include purchase of property, plant and equipment, leasing of land, cost of acquiring land use rights, and the acquisition of intangible assets through merger or acquisition activities. The Group's capital expenditures for the Reporting Period amounted to RMB 1,116.21 million, whilst the amount for the corresponding period of last year was RMB 849.61 million.

Sinopharm Group Co. Ltd. to Report First Half, 2015 Results on Aug 21, 2015

Sinopharm Group Co. Ltd. announced that they will report first half, 2015 results on Aug 21, 2015

Sinopharm Group Co. Ltd., Board Meeting, Aug 21, 2015

Sinopharm Group Co. Ltd., Board Meeting, Aug 21, 2015. Agenda: To consider and approve among other matters, the interim results of the company and its subsidiaries for the six months ended 30 June 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1099:HK $28.85 HKD 0.00

1099 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
China BCT Pharmacy Group Inc $0.0062 USD 0.00
Chongqing Tong Jun Ge Co Ltd CNY16.49 CNY +1.03
View Industry Companies

Industry Analysis


Industry Average

Valuation 1099 Industry Range
Price/Earnings 18.4x
Price/Sales 0.3x
Price/Book 2.2x
Price/Cash Flow 19.0x
TEV/Sales 0.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SINOPHARM GROUP CO-H, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at